Creative Biolabs

HER3 CAR mRNA-LNP

Datasheet Mdsd
COA

Cat. No.: TDLD-0825-LD44

HER3 CAR mRNA-LNP

HER3 CAR mRNA-LNP is a state-of-the-art messenger RNA (mRNA) lipid nanoparticle (LNP) system, specifically engineered for efficient in vitro and in vivo protein expression. This LNP encapsulates mRNA encoding the Chimeric Antigen Receptor (CAR) targeting Human Epidermal growth factor Receptor 3 (HER3), serving as an excellent tool for investigating novel CAR-T cell therapies against HER3-expressing cancers, particularly those with HER2 amplification, and for studying receptor-specific immune modulation in oncology research. Engineered with a proprietary lipid formulation for optimal mRNA encapsulation and delivery, it ensures high translation efficiency. Our LNP ensures uniform particle size, high encapsulation efficiency, stability, and effective delivery. Applications of HER3 CAR mRNA-LNP include monitoring CAR expression on transduced T cells and evaluating CAR-T cell functionality against HER3-positive targets. Please note that this product is intended for research purposes only.

Inquiry
SPECIFIC INQUIRY
Payload:
Modification:
Lipid Formulation:
Dye:
Concentration:
Quantity:
Clear All Inquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Payload Type CAR mRNA
Payload HER3 CAR mRNA
Modification Unmodified; N1-methyl-pseudouridine; 5-methoxyuridine; Other
Module Type Unconjugation
Lipid Formulation SM102
Dye Unlabeled
Application Gene Therapy; CAR-T
Format Liquid
Concentration 0.1 mg/mL; 0.2 mg/mL; Other (Please Specify)
Size 65-120 nm
PDI < 0.2
Zeta ± 20.0 mV
Encapsulate Efficiency >90%
Shipping Dry Ice
Storage Store at -80°C

Click the button below to contact us or submit your feedback about this product.

Customer Reviews and Q&As
Related Products
Online Inquiry

Customer Review

Creatibe Biolabs' custom LNP was the only solution that successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high efficiency and low toxicity.”

Dr. Evelyn Reed

Postdoctoral Researcher, Leading University

Our siRNA candidate was failing due to off-target toxicity, but Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our preclinical program.”

Ben Carter

Project Manager

Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform was the key to unlocking our candidate's full therapeutic potential.”

Dr. Kenji Tanaka

Principal Scientist, Large Pharma Corp

Our oncology drug's efficacy was limited by poor tumor accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting we needed, dramatically increasing the drug's therapeutic index.”

Dr. Clara Schmidt

Senior Scientist, Oncology Innovations Inc.

We required a delivery system that would only release its payload in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed flawlessly, minimizing systemic exposure.”

David Chen

Formulation Scientist

Outstanding expertise in antibody engineering.The team's attention to detail and innovative approaches have sianificantly accelerated our development timeline.

Sarah L.

Senior Research Scientist

Contact us for more information Get free consultations